Goldman Sachs lowered the firm’s price target on Doximity (DOCS) to $24 from $28 and keeps a Neutral rating on the shares. Doximity delivered results above expectations but showed further growth deceleration and introduced weaker-than-expected FY27 guidance alongside heavier AI investment plans that compress margins, leaving investors focused on slowing growth durability, intensifying competition, and uncertain monetization of its healthcare AI strategy, the analyst says in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $25 from $31 at Leerink
- Doximity downgraded to Neutral from Buy at BTIG
- Doximity Maintained at Buy as Analyst Sees Temporary Profit Trough and Long-Term Upside with Unchanged $47 Price Target
- Doximity: Buy Rating Backed by Solid Q4 Results, Cyclical Pharma Headwinds, and Long-Term AI Growth Strategy
- Doximity downgraded to Equal Weight from Overweight at Wells Fargo